Barclays analyst Luke Sergott raised the firm’s price target on Danaher to $290 from $260 and keeps an Overweight rating on the shares after its Q2 results. The quarter will likely mark a bottom and it’s a matter of timing when the stock starts to work, the analyst tells investors in a research note. Q3 guidance should also serve as the “risk-clearing” ahead of the FY24 BioPro industry growth framework, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR:
- Danaher Corporation Earnings Update: Did it Beat Estimate Forecasts?
- Beckman Coulter receives FDA clearance for DxC 500 AU Chemistry Analyzer
- Danaher sees Q3 base business core revenue down low-single digits
- Danaher reports Q2 adjusted EPS $2.05, consensus $2.01
- Danaher Reports Second Quarter 2023 Results